By using Helsinn Group website you agree to our use of cookies to enhance your experience.
We have updated our Terms of Use, Privacy & Cookies Policies in September 2020. To review them please follow the links below
Terms of Use | Privacy and Cookies Policy
9 March 2021
NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the close of a £15.2m (US $21m) Series B round. The syndicate was led by Claris Ventures and included 2Invest, 3B Future Health Fund and Astellas Venture Management alongside founding investor the CRT Pioneer Fund.
Thank you for your form submission, we will get in contact with you shortly.
